• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Novocure launches Optune, chemotherapy combo trial for glioblastoma

June 8, 2017 By Sarah Faulkner

NovocureNovocure (NSDQ:NVCR) said today that the 1st patient was enrolled in a Phase II pilot trial evaluating Optune with bevacizumab, a chemotherapy, for patients with refractory recurrent glioblastoma.

In recurrent GBM, Optune and bevacizumab are approved as monotherapies. Novocure’s consortium study is slated to evaluate the efficacy and safety of the Optune-chemo combo in patients with bevacizumab-refractory recurrent GBM.

The FDA-approved Optune mobile device delivers “tumor treating fields” – low-intensity, intermediate frequency, alternating electric fields – to inhibit cancer cell replication.

“The results of this trial will provide additional information to the brain tumor research community on the safety and effectiveness of using Optune in combination with bevacizumab in patients with bevacizumab-refractory recurrent GBM,” co-principal investigator Dr. Manmeet Ahluwalia said in prepared remarks. “These patients face a dismal prognosis and are in need of treatment options.”

The trial, which Novocure is conducting with the RTOG Foundation, is planned to enroll 85 patients. To assess the efficacy of Optune in combination chemotherapy, researchers plan to measure overall survival at 6 months. The company said it will also measure overall and progression-free survival from time of registration, response rates and toxicities.

“This is the 1st consortium study of TTFields, demonstrating the continued and mounting interest in Optune from the scientific community,” chief science officer & head of R&D Dr. Eilon Kirson said. “Our EF-11 Phase III pivotal trial in recurrent GBM patients suggested that in a subgroup of patients who were refractory to bevacizumab Optune monotherapy led to an extension in survival versus chemotherapy. We are excited that RTOG is researching the potential benefit of Optune together with bevacizumab in this difficult-to-treat population of patients.”

“For 40 years, RTOG has conducted studies designed to improve the survival and quality of life of cancer patients,” co-principal investigator Dr. Jeffrey Raizer added. “RTOG is excited to partner with Novocure on this important study, and I am pleased to be able to offer Optune to patients in this study.”

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Neurological, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: NovoCure

IN CASE YOU MISSED IT

  • Medtronic to invest $50M in India Diabetes center
  • Flat Medical partners with Mercury Medical on smart syringe distribution
  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS